Sangamo Therapeutics, Inc. (SGMO)
Stock Price:
$11.47 USD
-0.15 (-1.29%)
Updated Aug 14, 2020 12:20 PM EDT - Market open
Key Info
| Market Cap |
1.62B |
| Revenue (ttm) |
111.44M |
| Net Income (ttm) |
-101.59M |
| Shares Out |
140.99M |
| EPS (ttm) |
-0.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$11.47 |
| Previous Close |
$11.62 |
| Change ($) |
-0.15 |
| Change (%) |
-1.29% |
| Day's Open |
11.60 |
| Day's Range |
11.44 - 11.65 |
| Day's Volume |
240,286 |
| 52-Week Range |
4.81 - 12.91 |
More Stats
| Market Cap |
1.62B |
| Enterprise Value |
991.51M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
140.99M |
| Float |
116.44M |
| EPS (basic) |
-0.82 |
| EPS (diluted) |
-0.84 |
| FCF / Share |
0.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
3.95% |
| Payout Ratio |
n/a |
| Shares Short |
19.66M |
| Short Ratio |
11.87 |
| Short % of Float |
13.14% |
| Beta |
2.26 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
25.35 |
| PS Ratio |
14.51 |
| PB Ratio |
3.22 |
| Revenue |
111.44M |
| Operating Income |
-110.20M |
| Net Income |
-101.59M |
| Free Cash Flow |
63.80M |
| Net Cash |
625.62M |
| Net Cash / Share |
4.44 |
| Gross Margin |
-39.03% |
| Operating Margin |
-98.89% |
| Profit Margin |
-91.20% |
| FCF Margin |
57.26% |
| ROA |
-8.78% |
| ROE |
-21.28% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
6 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.14*
(75.59% upside)
Low
11.0
Current: $11.47
High
36.0
Target: 20.14
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 102 | 84.45 | 36.57 | 19.39 | 39.54 | 45.87 | 24.13 | 21.66 | 10.32 | 20.81 |
| Revenue Growth | 21.29% | 130.95% | 88.6% | -50.96% | -13.8% | 90.07% | 11.44% | 109.86% | -50.4% | - |
| Gross Profit | 102 | 84.45 | 36.57 | 19.39 | 39.54 | 45.87 | 24.13 | 21.66 | 10.32 | 20.81 |
| Operating Income | -105 | -77.15 | -56.36 | -72.56 | -46.86 | -26.78 | -26.71 | -22.20 | -35.82 | -24.94 |
| Net Income | -95.19 | -68.33 | -54.57 | -71.66 | -40.70 | -26.42 | -26.62 | -22.26 | -35.75 | -24.85 |
| Shares Outstanding | 112 | 96.94 | 78.08 | 70.55 | 69.76 | 67.02 | 55.97 | 52.74 | 50.51 | 45.17 |
| Earnings Per Share | -0.85 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 |
| Operating Cash Flow | -144 | 36.55 | 11.18 | -65.88 | -33.72 | -5.68 | -19.48 | -8.08 | -25.90 | -23.93 |
| Capital Expenditures | -20.68 | -43.07 | -3.75 | -0.73 | - | - | -0.43 | -0.72 | -0.58 | -0.70 |
| Free Cash Flow | -165 | -6.52 | 7.43 | -66.62 | -33.72 | -5.68 | -19.91 | -8.81 | -26.47 | -24.63 |
| Cash & Equivalents | 362 | 400 | 243 | 143 | 209 | 179 | 93.13 | 63.55 | 84.13 | 60.29 |
| Total Debt | 41.19 | 27.69 | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 321 | 372 | 243 | 143 | 209 | 179 | 93.13 | 63.55 | 84.13 | 60.29 |
| Assets | 638 | 590 | 287 | 158 | 217 | 243 | 141 | 82.53 | 87.34 | 63.00 |
| Liabilities | 205 | 223 | 98.84 | 21.70 | 24.80 | 36.58 | 19.13 | 17.64 | 7.20 | 7.09 |
| Book Value | 433 | 367 | 188 | 136 | 192 | 207 | 122 | 64.90 | 80.13 | 55.91 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Sangamo Therapeutics, Inc. |
| Country |
United States |
| Employees |
354 |
| CEO |
Alexander D. Macrae |
Stock Information
| Ticker Symbol |
SGMO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SGMO |
| IPO Date |
April 6, 2000 |
Description
Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.